The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Biopharmaceutical CMO & CRO-Global Market Insights and Sales Trends 2025
Synopsis
The global Biopharmaceutical CMO & CRO market size is expected to reach US$ 27950 million by 2029, growing at a CAGR of 4.4% from 2023 to 2029. The market is mainly driven by the significant applications of Biopharmaceutical CMO & CRO in various end use industries. The expanding demands from the Contract Manufacturing and Contract Research, are propelling Biopharmaceutical CMO & CRO market. Biologics, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Biosimilars segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Biopharmaceutical CMO & CRO, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Biopharmaceutical CMO & CRO market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Biopharmaceutical CMO & CRO market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Biopharmaceutical CMO & CRO sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Biopharmaceutical CMO & CRO covered in this report include Lonza, Boehringer Ingelheim GmbH, Rentschler Biotechnologie GmbH, Inno Biologics Sdn Bhd, JRS Pharma (Celonic GmbH), BIOMEVA GmbH, ProBioGen, FUJIFILM Diosynth Biotechnologies U.S.A., Inc. and TOYOBO CO., LTD, etc.
The global Biopharmaceutical CMO & CRO market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Lonza
Boehringer Ingelheim GmbH
Rentschler Biotechnologie GmbH
Inno Biologics Sdn Bhd
JRS Pharma (Celonic GmbH)
BIOMEVA GmbH
ProBioGen
FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
TOYOBO CO., LTD
Samsung BioLogics
Patheon
CMC Biologics
Binex Co., Ltd.
AbbVie Inc.
WuXi Biologics.
Global Biopharmaceutical CMO & CRO market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Biopharmaceutical CMO & CRO market, Segment by Type:
Biologics
Biosimilars
Global Biopharmaceutical CMO & CRO market, by Application
Contract Manufacturing
Contract Research
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Biopharmaceutical CMO & CRO companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The global Biopharmaceutical CMO & CRO market size is expected to reach US$ 27950 million by 2029, growing at a CAGR of 4.4% from 2023 to 2029. The market is mainly driven by the significant applications of Biopharmaceutical CMO & CRO in various end use industries. The expanding demands from the Contract Manufacturing and Contract Research, are propelling Biopharmaceutical CMO & CRO market. Biologics, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Biosimilars segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Biopharmaceutical CMO & CRO, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Biopharmaceutical CMO & CRO market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Biopharmaceutical CMO & CRO market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Biopharmaceutical CMO & CRO sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Biopharmaceutical CMO & CRO covered in this report include Lonza, Boehringer Ingelheim GmbH, Rentschler Biotechnologie GmbH, Inno Biologics Sdn Bhd, JRS Pharma (Celonic GmbH), BIOMEVA GmbH, ProBioGen, FUJIFILM Diosynth Biotechnologies U.S.A., Inc. and TOYOBO CO., LTD, etc.
The global Biopharmaceutical CMO & CRO market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Lonza
Boehringer Ingelheim GmbH
Rentschler Biotechnologie GmbH
Inno Biologics Sdn Bhd
JRS Pharma (Celonic GmbH)
BIOMEVA GmbH
ProBioGen
FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
TOYOBO CO., LTD
Samsung BioLogics
Patheon
CMC Biologics
Binex Co., Ltd.
AbbVie Inc.
WuXi Biologics.
Global Biopharmaceutical CMO & CRO market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Biopharmaceutical CMO & CRO market, Segment by Type:
Biologics
Biosimilars
Global Biopharmaceutical CMO & CRO market, by Application
Contract Manufacturing
Contract Research
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Biopharmaceutical CMO & CRO companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Biopharmaceutical CMO & CRO
1.1 Biopharmaceutical CMO & CRO Market Overview
1.1.1 Biopharmaceutical CMO & CRO Product Scope
1.1.2 Biopharmaceutical CMO & CRO Market Status and Outlook
1.2 Global Biopharmaceutical CMO & CRO Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Biopharmaceutical CMO & CRO Market Size by Region (2018-2029)
1.4 Global Biopharmaceutical CMO & CRO Historic Market Size by Region (2018-2023)
1.5 Global Biopharmaceutical CMO & CRO Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Biopharmaceutical CMO & CRO Market Size (2018-2029)
1.6.1 North America Biopharmaceutical CMO & CRO Market Size (2018-2029)
1.6.2 Europe Biopharmaceutical CMO & CRO Market Size (2018-2029)
1.6.3 Asia-Pacific Biopharmaceutical CMO & CRO Market Size (2018-2029)
1.6.4 Latin America Biopharmaceutical CMO & CRO Market Size (2018-2029)
1.6.5 Middle East & Africa Biopharmaceutical CMO & CRO Market Size (2018-2029)
2 Biopharmaceutical CMO & CRO Market by Type
2.1 Introduction
2.1.1 Biologics
2.1.2 Biosimilars
2.2 Global Biopharmaceutical CMO & CRO Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Biopharmaceutical CMO & CRO Historic Market Size by Type (2018-2023)
2.2.2 Global Biopharmaceutical CMO & CRO Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Biopharmaceutical CMO & CRO Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Biopharmaceutical CMO & CRO Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Biopharmaceutical CMO & CRO Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Biopharmaceutical CMO & CRO Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Biopharmaceutical CMO & CRO Revenue Breakdown by Type (2018-2029)
3 Biopharmaceutical CMO & CRO Market Overview by Application
3.1 Introduction
3.1.1 Contract Manufacturing
3.1.2 Contract Research
3.2 Global Biopharmaceutical CMO & CRO Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Biopharmaceutical CMO & CRO Historic Market Size by Application (2018-2023)
3.2.2 Global Biopharmaceutical CMO & CRO Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Biopharmaceutical CMO & CRO Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Biopharmaceutical CMO & CRO Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Biopharmaceutical CMO & CRO Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Biopharmaceutical CMO & CRO Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Biopharmaceutical CMO & CRO Revenue Breakdown by Application (2018-2029)
4 Biopharmaceutical CMO & CRO Competition Analysis by Players
4.1 Global Biopharmaceutical CMO & CRO Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Biopharmaceutical CMO & CRO as of 2022)
4.3 Date of Key Players Enter into Biopharmaceutical CMO & CRO Market
4.4 Global Top Players Biopharmaceutical CMO & CRO Headquarters and Area Served
4.5 Key Players Biopharmaceutical CMO & CRO Product Solution and Service
4.6 Competitive Status
4.6.1 Biopharmaceutical CMO & CRO Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Lonza
5.1.1 Lonza Profile
5.1.2 Lonza Main Business
5.1.3 Lonza Biopharmaceutical CMO & CRO Products, Services and Solutions
5.1.4 Lonza Biopharmaceutical CMO & CRO Revenue (US$ Million) & (2018-2023)
5.1.5 Lonza Recent Developments
5.2 Boehringer Ingelheim GmbH
5.2.1 Boehringer Ingelheim GmbH Profile
5.2.2 Boehringer Ingelheim GmbH Main Business
5.2.3 Boehringer Ingelheim GmbH Biopharmaceutical CMO & CRO Products, Services and Solutions
5.2.4 Boehringer Ingelheim GmbH Biopharmaceutical CMO & CRO Revenue (US$ Million) & (2018-2023)
5.2.5 Boehringer Ingelheim GmbH Recent Developments
5.3 Rentschler Biotechnologie GmbH
5.3.1 Rentschler Biotechnologie GmbH Profile
5.3.2 Rentschler Biotechnologie GmbH Main Business
5.3.3 Rentschler Biotechnologie GmbH Biopharmaceutical CMO & CRO Products, Services and Solutions
5.3.4 Rentschler Biotechnologie GmbH Biopharmaceutical CMO & CRO Revenue (US$ Million) & (2018-2023)
5.3.5 Inno Biologics Sdn Bhd Recent Developments
5.4 Inno Biologics Sdn Bhd
5.4.1 Inno Biologics Sdn Bhd Profile
5.4.2 Inno Biologics Sdn Bhd Main Business
5.4.3 Inno Biologics Sdn Bhd Biopharmaceutical CMO & CRO Products, Services and Solutions
5.4.4 Inno Biologics Sdn Bhd Biopharmaceutical CMO & CRO Revenue (US$ Million) & (2018-2023)
5.4.5 Inno Biologics Sdn Bhd Recent Developments
5.5 JRS Pharma (Celonic GmbH)
5.5.1 JRS Pharma (Celonic GmbH) Profile
5.5.2 JRS Pharma (Celonic GmbH) Main Business
5.5.3 JRS Pharma (Celonic GmbH) Biopharmaceutical CMO & CRO Products, Services and Solutions
5.5.4 JRS Pharma (Celonic GmbH) Biopharmaceutical CMO & CRO Revenue (US$ Million) & (2018-2023)
5.5.5 JRS Pharma (Celonic GmbH) Recent Developments
5.6 BIOMEVA GmbH
5.6.1 BIOMEVA GmbH Profile
5.6.2 BIOMEVA GmbH Main Business
5.6.3 BIOMEVA GmbH Biopharmaceutical CMO & CRO Products, Services and Solutions
5.6.4 BIOMEVA GmbH Biopharmaceutical CMO & CRO Revenue (US$ Million) & (2018-2023)
5.6.5 BIOMEVA GmbH Recent Developments
5.7 ProBioGen
5.7.1 ProBioGen Profile
5.7.2 ProBioGen Main Business
5.7.3 ProBioGen Biopharmaceutical CMO & CRO Products, Services and Solutions
5.7.4 ProBioGen Biopharmaceutical CMO & CRO Revenue (US$ Million) & (2018-2023)
5.7.5 ProBioGen Recent Developments
5.8 FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
5.8.1 FUJIFILM Diosynth Biotechnologies U.S.A., Inc. Profile
5.8.2 FUJIFILM Diosynth Biotechnologies U.S.A., Inc. Main Business
5.8.3 FUJIFILM Diosynth Biotechnologies U.S.A., Inc. Biopharmaceutical CMO & CRO Products, Services and Solutions
5.8.4 FUJIFILM Diosynth Biotechnologies U.S.A., Inc. Biopharmaceutical CMO & CRO Revenue (US$ Million) & (2018-2023)
5.8.5 FUJIFILM Diosynth Biotechnologies U.S.A., Inc. Recent Developments
5.9 TOYOBO CO., LTD
5.9.1 TOYOBO CO., LTD Profile
5.9.2 TOYOBO CO., LTD Main Business
5.9.3 TOYOBO CO., LTD Biopharmaceutical CMO & CRO Products, Services and Solutions
5.9.4 TOYOBO CO., LTD Biopharmaceutical CMO & CRO Revenue (US$ Million) & (2018-2023)
5.9.5 TOYOBO CO., LTD Recent Developments
5.10 Samsung BioLogics
5.10.1 Samsung BioLogics Profile
5.10.2 Samsung BioLogics Main Business
5.10.3 Samsung BioLogics Biopharmaceutical CMO & CRO Products, Services and Solutions
5.10.4 Samsung BioLogics Biopharmaceutical CMO & CRO Revenue (US$ Million) & (2018-2023)
5.10.5 Samsung BioLogics Recent Developments
5.11 Patheon
5.11.1 Patheon Profile
5.11.2 Patheon Main Business
5.11.3 Patheon Biopharmaceutical CMO & CRO Products, Services and Solutions
5.11.4 Patheon Biopharmaceutical CMO & CRO Revenue (US$ Million) & (2018-2023)
5.11.5 Patheon Recent Developments
5.12 CMC Biologics
5.12.1 CMC Biologics Profile
5.12.2 CMC Biologics Main Business
5.12.3 CMC Biologics Biopharmaceutical CMO & CRO Products, Services and Solutions
5.12.4 CMC Biologics Biopharmaceutical CMO & CRO Revenue (US$ Million) & (2018-2023)
5.12.5 CMC Biologics Recent Developments
5.13 Binex Co., Ltd.
5.13.1 Binex Co., Ltd. Profile
5.13.2 Binex Co., Ltd. Main Business
5.13.3 Binex Co., Ltd. Biopharmaceutical CMO & CRO Products, Services and Solutions
5.13.4 Binex Co., Ltd. Biopharmaceutical CMO & CRO Revenue (US$ Million) & (2018-2023)
5.13.5 Binex Co., Ltd. Recent Developments
5.14 AbbVie Inc.
5.14.1 AbbVie Inc. Profile
5.14.2 AbbVie Inc. Main Business
5.14.3 AbbVie Inc. Biopharmaceutical CMO & CRO Products, Services and Solutions
5.14.4 AbbVie Inc. Biopharmaceutical CMO & CRO Revenue (US$ Million) & (2018-2023)
5.14.5 AbbVie Inc. Recent Developments
5.15 WuXi Biologics.
5.15.1 WuXi Biologics. Profile
5.15.2 WuXi Biologics. Main Business
5.15.3 WuXi Biologics. Biopharmaceutical CMO & CRO Products, Services and Solutions
5.15.4 WuXi Biologics. Biopharmaceutical CMO & CRO Revenue (US$ Million) & (2018-2023)
5.15.5 WuXi Biologics. Recent Developments
6 North America
6.1 North America Biopharmaceutical CMO & CRO Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Biopharmaceutical CMO & CRO Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Biopharmaceutical CMO & CRO Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Biopharmaceutical CMO & CRO Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Biopharmaceutical CMO & CRO Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Biopharmaceutical CMO & CRO Market Dynamics
11.1 Biopharmaceutical CMO & CRO Industry Trends
11.2 Biopharmaceutical CMO & CRO Market Drivers
11.3 Biopharmaceutical CMO & CRO Market Challenges
11.4 Biopharmaceutical CMO & CRO Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest IT & Electronics Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
